glp 1 and chronic kidney disease GLP-1 agonists in the treatment of in type 2 diabetes obesity glp-1 and chronic kidney disease

For Peyronie's disease : 1 gram of acetyl-L-carnitine has been taken twice daily for 3 months

Bariatric surgery results in increased secretion of GLP-1 and PYY and co-infusion of PYY336 and GLP-1 elicit at least additive anorectic effect with ~30% reduction in food intake exceeding the 15%20% reduction predicted to sustain a weight loss 10% in one year (98101)

11.27.21 Aliza Azam said: Many thanks for your prompt response

Disrupted copper homeostasis contributes to numerous neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), making GHK-Cu's copper-regulating properties particularly relevant to neurological research

More specifically, GLP-1 RAs have been linked to increased bone formation markers, such as P1NP, osteocalcin, and bone-specific alkaline phosphatase, while simultaneously reducing bone resorption markers, like -CTX (10, 11, 12)

Available from: Tolhurst G, Reimann F, Gribble FM